Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
Discontinued [GID-TA10970]
Discontinued [GID-TAG390]
Discontinued [GID-TAG402]
Discontinued [GID-TAG396]
Discontinued [GID-TAG372]
Discontinued [GID-MT544]
Discontinued [GID-TAG378]
Discontinued [GID-CGWAVE0771]
Discontinued [GID-TA10236]
Discontinued [GID-TAG375]
Discontinued [GID-TAG398]
Discontinued [GID-TAG371]
Discontinued [GID-TAG370]
Discontinued [GID-TAG411]
Discontinued [GID-TA10462]
Discontinued [GID-MT81]
Discontinued [GID-TAG404]
Discontinued [GID-TAG368]
Discontinued [GID-MT516]
Discontinued [GID-TAG239]
Discontinued [GID-MT267]
Discontinued [GID-CGWAVE0773]
Discontinued [GID-MT517]
Discontinued [GID-MT163]
Discontinued [GID-TAG385]
Discontinued [GID-TAG400]
Discontinued [GID-TAG416]
Discontinued [GID-TAG408]
Discontinued [GID-MT117]
Discontinued [GID-TA10087]
Discontinued [GID-TAG377]
Discontinued [GID-TAG241]
Discontinued [GID-MT130]
Discontinued [GID-TA10088]
Discontinued [GID-MT510]
Discontinued [GID-TA10502]
Discontinued [GID-TAG414]
Discontinued [GID-NG10059]
Discontinued [GID-MT536]
Discontinued [GID-TAG399]
Discontinued [GID-TAG511]
Discontinued [GID-TAG382]
Discontinued [GID-TAG393]
Discontinued [GID-TAG397]
Discontinued [GID-TAG374]
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
Discontinued [GID-TA10081]
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.